ArticleCardiovascular therapeutics2026
The miR-511-3p/ATP2A2 Axis Is Required for Propofol-Mediated Cardioprotection Against Hypoxia/Reoxygenation Injury.
Article in Cardiovascular therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundPropofol (PPF) alleviates myocardial ischemia/reperfusion injury (MIRI), yet no existing studies have clarified the function of microRNA-511-3p (miR-511-3p) in cardiac injury or its link to PPF's cardioprotection. PURPOSE: This study clarified how the miR-511-3p/ATPase sarcoplasmic/endoplasmic reticulum Ca
methodsH/R damage models were established in H9c2 cells. Cell viability was measured via the CCK-8 assay, and flow cytometry was used to quantify the proportion of apoptotic cells. Cellular reactive oxygen species (ROS) levels were assessed using the DCFH-DA fluorescent staining method. ELISA and colorimetric tests were combined to measure cardiac injury markers, inflammatory mediators, and oxidative stress-related molecules. RT-qPCR was applied to test the expression levels of miR-511-3p and ATP2A2. Dual-luciferase reporter assays were carried out to confirm the direct binding interaction between the two molecules.
resultsPPF markedly boosted the viability and restrained apoptosis of H9c2 cells subjected to H/R treatment. It also reduced the release of cardiac injury markers and eased excessive oxidative stress and inflammatory responses. H/R exposure raised miR-511-3p abundance, an alteration that PPF treatment could reverse. Forced miR-511-3p expression partially abolished the cardioprotective benefits brought by PPF. ATP2A2 was verified as a direct target of miR-511-3p, whose expression was suppressed by this miRNA. Upregulating ATP2A2 counteracted cell damage triggered by miR-511-3p overexpression.
conclusionsPPF might mitigate H/R-triggered cardiomyocyte damage, possibly through inhibiting miR-511-3p and increasing its target ATP2A2, and this molecular axis may offer a tentative therapeutic reference for MIRI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.